About Pfizer Limited 

Pfizer Limited operates as a leading Indian pharmaceuticals firm which belongs to Pfizer Inc.’s worldwide network since 1950 when it first entered the Indian market. The Company reaches its 75th year in India during FY 2024-25 after seven decades of delivering fundamental therapies throughout the nation. The company started as a public corporation after gaining Bombay Stock Exchange listing in 1966. The IPO proceeds were utilised for commissioning the Thane Plant. It made its debut on the National Stock Exchange in 1999. 

Pfizer Limited maintains operations in Pharmaceuticals as its single business segment and operates a manufacturing facility at Verna Goa while maintaining corporate offices in Mumbai .

The company distributes established brand medicines across several therapeutic fields including vitamins and cough relief products. The two major brands Becosules and Corex Dx operate in the market because Corex Dx dominates dry cough sales with a 15% value share and a 13% volume share. The Company maintains an 11% market presence in Women’s Healthcare through its two main brands Folvite and Ovral L. Pacitane commands an 68 Per cent market position within Neuroscience while Ativan functions as a leading anxiolytic medication with a 6% market share.

Pfizer Limited’s Geographic Presence 

Pfizer Limited provides its products to all 28 States and 8 Union Territories across India while exporting to Nepal, Sri Lanka, Bangladesh, Ireland and the Netherlands. Exports comprised 5% of total turnover during FY 2024-25.

Pfizer Limited Key milestones include

• 1966: Listed on the Bombay Stock Exchange; 1999: Listed on NSE .
• 1970: Leadership fully Indianised; 1972–73: Highest export performance award;
• 1974–75: National Safety Award and major safety milestones at Thane plant.
• 1995: Established India’s first dedicated clinical research unit.
• 2001: Parke-Davis (India) Ltd. amalgamated; 2002: Goa tablet plant commissioned;
• 2003: Pharmacia Healthcare Ltd. amalgamated; 2014: Wyeth Limited amalgamated, adding Vaccines and Women’s Healthcare to the portfolio.

Pfizer Limited Key Management

• Pradip Shah – Chairman (Non-Executive, Non-Independent Director).
• Meenakshi Nevatia – Managing Director.
• Amit Agarwal – Chief Financial Officer and Executive Director.
• P. Rengan – Executive Director – Plant Operations.
• Prajeet Nair – Company Secretary.

Latest Updates on Pfizer Limited 

• The Company executed the transfer of its leasehold properties at Thane to Zoetis Pharmaceutical Research Private Limited through a transaction reported in the Board’s Report for FY 2024-25.
• The IM segment of Pfizer built stronger relationships with medical prescribers because IM brands received prescriptions from 2.7 Lakh healthcare professionals during FY 2025 which showed a 3% annual growth from increased speciality adoption and better distribution networks.
• Zinforo emerged as a fresh cephalosporin medication which Pfizer introduced for treating adult patients with community-acquired pneumonia thus expanding its critical care therapeutic options.
• During the year the company formed a partnership with Mylan Pharmaceuticals Private Limited to expand its capabilities in neuropsychiatry.
• Pfizer announced its partnership with NIPER (Ahmedabad) to support Indian healthcare innovation.
• The Company in India utilizes generative AI tools safely to boost employee productivity and operational effectiveness.